RxSight (RXST) Projected to Post Earnings on Tuesday

RxSight (NASDAQ:RXST) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect RxSight to post earnings of ($0.29) per share and revenue of $27.19 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $33.74 million during the quarter, compared to analyst estimates of $32.55 million. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. On average, analysts expect RxSight to post ($1.03) EPS for the current fiscal year and ($1.22) EPS for the next fiscal year.

RxSight Stock Down 1.8%

Shares of RXST opened at $4.93 on Tuesday. The stock has a market cap of $205.04 million, a price-to-earnings ratio of -4.36 and a beta of 1.15. RxSight has a 12 month low of $4.40 and a 12 month high of $13.22. The company has a 50-day moving average price of $5.50 and a two-hundred day moving average price of $6.48.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on RXST shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of RxSight in a research note on Tuesday, September 8th. Jefferies Financial Group decreased their price target on RxSight from $6.50 to $5.75 and set a “hold” rating on the stock in a research note on Tuesday, September 22nd. Wall Street Zen cut RxSight from a “hold” rating to a “sell” rating in a research report on Sunday. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of RxSight in a research note on Tuesday, July 7th. Finally, UBS Group increased their price objective on RxSight from $5.50 to $6.30 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $8.17.

Insider Activity at RxSight

In other news, insider M Kurtz sold 5,100 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the transaction, the insider directly owned 71,775 shares of the company’s stock, valued at $499,554. The trade was a 6.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Mark Wilterding sold 7,765 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $54,044.40. Following the sale, the chief financial officer owned 25,049 shares in the company, valued at approximately $174,341.04. This trade represents a 23.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,947 shares of company stock worth $117,951 over the last three months. 10.05% of the stock is owned by company insiders.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to customize a patient’s vision after surgery.

Its primary product is the RxSight Light Adjustable Lens, an intraocular lens implanted during cataract surgery. After implantation, the lens can be adjusted using ultraviolet light treatments delivered by the company’s Light Delivery Device, enabling physicians to refine the lens power based on the patient’s postoperative visual needs.